It’s a fair point Spec. So the rationale here is to...

It’s a fair point Spec.

So the rationale here is to hold/increase your position in anticipation of a takeover at a decent premium?

Maybe the market is wowed by the scoping study, driving up the share price quickly too. So we would get an uplift without a predator arriving on the scene.

But even if the scoping study is a good one, I now have serious doubts about the inclination/capacity of the board to move things forward quickly from that point.

It’s as if they don’t realise that investors have alternative companies in which to put their money. There is an opportunity cost to being patient with GBR. In fact, it’s a cost that has already been borne by a lot of us.

I’m going to hang around for the scoping study. But if a bid doesn’t then come in, or if we then get news of another capital raise primarily to explore more of Sidewell, that’ll be long enough of a wait for me.